Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00415-021-10444-6 http://scihub22266oqcxt.onion/10.1007/s00415-021-10444-6 33606070!7892700!33606070     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33606070&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Neurol 2021 ; 268 (9): 3116-3124 Nephropedia Template TP {{tp|p=33606070|t=2021. Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms |pdf=|usr=}}{{33606070}} gab.com Text Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms JO: J Neurol http://www.kidney.de/pget.php?&tw=1&pmid=33606070 #FOAvip SARS-CoV-2 infection can associate diverse neurological manifestations. Several studies have provided proof to support the theory of neurotropic involvement of SARS-CoV-2. Alpha-synuclein has been described as a native antiviral factor within neurons, and upregulation of this protein can be seen in animals that suffered other neuroinvasive infections. To assess if increased expression of this protein takes place in COVID-19 patients with neurological symptoms, we analyzed serum total alpha-synuclein levels in three groups: seven COVID-19 patients with myoclonus, Parkinsonism and/or encephalopathy; thirteen age- and sex-matched COVID-19 patients without neurological involvement and eight age- and sex-matched healthy controls. We did not find differences among them. In a subset of four patients, the change in serum alpha-synuclein before and after the onset of neurological symptoms was not significant either. Cerebrospinal fluid alpha-synuclein levels were also similar between neurological COVID-19 and healthy controls. Overall, these results cannot support the hypothesis of alpha-synuclein upregulation in humans with neurological symptoms in COVID-19. Further research taking into account a larger group of COVID-19 patients including the whole spectrum of neurological manifestations and disease severity is needed. Twit Text FOAVip Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms ????J Neurol http://www.kidney.de/pget.php?&tw=1&pmid=33606070 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33606070 #FOAvip English Wikipedia <ref>{{Cite pmid|33606070}}</ref> Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms #MMPMID33606070 Blanco-Palmero VA; Azcarate-Diaz FJ; Ruiz-Ortiz M; Laespada-Garcia MI; Rabano-Suarez P; Mendez-Guerrero A; Aramendi-Ramos M; Eguiburu JL; Perez-Rivilla A; Marchan-Lopez A; Rubio-Fernandez M; Carro E; Gonzalez de la Aleja J J Neurol 2021[Sep]; 268 (9): 3116-3124 PMID33606070show ga SARS-CoV-2 infection can associate diverse neurological manifestations. Several studies have provided proof to support the theory of neurotropic involvement of SARS-CoV-2. Alpha-synuclein has been described as a native antiviral factor within neurons, and upregulation of this protein can be seen in animals that suffered other neuroinvasive infections. To assess if increased expression of this protein takes place in COVID-19 patients with neurological symptoms, we analyzed serum total alpha-synuclein levels in three groups: seven COVID-19 patients with myoclonus, Parkinsonism and/or encephalopathy; thirteen age- and sex-matched COVID-19 patients without neurological involvement and eight age- and sex-matched healthy controls. We did not find differences among them. In a subset of four patients, the change in serum alpha-synuclein before and after the onset of neurological symptoms was not significant either. Cerebrospinal fluid alpha-synuclein levels were also similar between neurological COVID-19 and healthy controls. Overall, these results cannot support the hypothesis of alpha-synuclein upregulation in humans with neurological symptoms in COVID-19. Further research taking into account a larger group of COVID-19 patients including the whole spectrum of neurological manifestations and disease severity is needed. |*Brain Diseases[MESH] |*COVID-19[MESH] |Animals[MESH] |Humans[MESH] |Neurons[MESH] |SARS-CoV-2[MESH]Serum and CSF alpha-synuclein levels do not change in COVID-19 patient(epmc).pdf DeepDyve Pubget Overpricing